INTRODUCTION: Neoadjuvant nivolumab and cabozantinib in locally advanced renal cell carcinoma in a horseshoe kidney is a novel therapeutic approach in the preoperative setting. METHODS: We report a case of a 52-year old male who presented with a large inoperable tumor of the horseshoe kidney and achieved major partial radiologic response after neoadjuvant therapy with nivolumab and cabozantinib leading to radical resection of the tumor. The patient remains tumor free on the subsequent follow-up and his renal function is only mildly decreased. The systemic treatment was complicated by hepatotoxicity leading to early nivolumab withdrawal. RESULTS: Currently, the combination therapy based on immune checkpoint inhibitors and tyrosine kinase inhibitors represents the treatment of choice in treatment-naïve patients with metastatic renal cell carcinoma in any prognostic group. The neoadjuvant treatment approach is being tested in prospective clinical trials and results are eagerly awaited. Renal cell carcinoma in a horseshoe kidney is an uncommon finding that is always challenging. Additionally, management guidance in this patient population is lacking. In some patients neoadjuvant therapy could be the only way to preserve kidney function. The initial treatment strategy should be individualized to patient needs aiming at the radical resection of the primary tumor as the only chance of getting the tumor under control in the long term. CONCLUSION: Herein, we highlight the feasibility of neoadjuvant systemic therapy with nivolumab and cabozantinib allowing the subsequent performance of radical tumor resection with negative margins in a patient with advanced renal cell carcinoma in a horseshoe kidney, removing the primary tumor while sparing the patient from lifelong dialysis.

Department of Clinical and Molecular Pathology Faculty of Medicine and Dentistry University Hospital Olomouc Palacky University Olomouc Czechia

Department of Oncology Faculty of Medicine and Dentistry University Hospital Olomouc Palacky University Olomouc Czechia

Department of Urology Faculty of Medicine and Dentistry University Hospital Olomouc Palacky University Olomouc Czechia

Zobrazit více v PubMed

Motzer R, Rini BI, McDermott DF, Frontera OA, Hammers HJ, Carducci MA, et al. . Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol (2019) 20(10):1370–85. doi: 10.1016/S1470-2045(19)30413-9 PubMed DOI PMC

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. . Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New Engl J Med (2019) 380(12):1103–15. doi: 10.1056/NEJMoa1816047 PubMed DOI PMC

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. . Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. New Engl J Med (2021) 384(9):829–41. doi: 10.1056/NEJMoa2026982 PubMed DOI PMC

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. . Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New Engl J Med (2019) 380(12):1116–27. doi: 10.1056/NEJMoa1816714 PubMed DOI

Motzer RJ, Porta C, Eto M, Powles T, Grunwald V, Hutson TE, et al. . Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a firstline treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). J Clin Oncol (2021) 39(6). doi: 10.1200/JCO.2021.39.6_suppl.269 DOI

Bindayi A, Hamilton ZA, McDonald ML, Yim K, Millard F, McKay RR, et al. . Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Urol Oncol (2018) 36(1):31–7. doi: 10.1016/j.urolonc.2017.07.015 PubMed DOI

Watson DD, Farha NM, Kallail KJ, Dakhil S, Farha AJ. From radical to partial nephrectomy in the setting of solitary functioning kidney: neoadjuvant treatment of renal cell carcinoma. Rev Urol (2020) 22(3):126–9. PubMed PMC

Bigot P, Fardoun T, Bernhard JC, Xylinas E, Berger J, Rouprêt M, et al. . Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World J Urol (2014) 32(1):109–14. doi: 10.1007/s00345-013-1088-1 PubMed DOI

Robert G, Gabbay G, Bram R, Wallerand H, Deminière C, Cornelis F, et al. . Case study of the month. complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol (2009) 55(6):1477–80. doi: 10.1016/j.eururo.2008.12.036 PubMed DOI

Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol (2016) 8(2):130–41. doi: 10.1177/1756287215612962 PubMed DOI PMC

Rini BI, Garcia J, Elson P, Wood L, Shah S, Stephenson A, et al. . The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol (2012) 187(5):1548–54. doi: 10.1016/j.juro.2011.12.075 PubMed DOI

Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, et al. . Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol (2014) 66(5):874–80. doi: 10.1016/j.eururo.2014.01.035 PubMed DOI PMC

Bilen MA, Jiang JF, Jansen CS, Brown JT, Harik LR, Sekhar A, et al. . Neoadjuvant cabozantinib in an unresectable locally advanced renal cell carcinoma patient leads to downsizing of tumor enabling surgical resection: a case report. Front Oncol (2020) 10:622134. doi: 10.3389/fonc.2020.622134 PubMed DOI PMC

de Velasco G, Carril-Ajuria L, Guerrero-Ramos F, Alonso-Gordoa T, Rodríguez-Moreno JF, Carretero A, et al. . A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial. Oncotarget. (2020) 11(47):4457–62. doi: 10.18632/oncotarget.27807 PubMed DOI PMC

Roy AM, Briggler A, Tippit D, Dawson K, Verma R. Neoadjuvant cabozantinib in renal-cell carcinoma: a brief review. Clin Genitourin Cancer (2020) 18(6):e688–e91. doi: 10.1016/j.clgc.2020.04.003 PubMed DOI

Jurascheck L, Yang YH, Jackson-Spence F, Toms C, Sng CC, Flanders L, et al. . 1467P optimal neoadjuvant treatment choice for localised renal cell carcinoma. Ann Oncol (2022) 33:S1217. doi: 10.1016/j.annonc.2022.07.1570 DOI

Gorin MA, Patel HD, Rowe SP, Hahn NM, Hammers HJ, Pons A, et al. . Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma. Eur Urol Oncol (2021) 5(1):113–7. doi: 10.1016/j.euo.2021.04.002 PubMed DOI PMC

Allaf M, Kim SE, Harshman LC, McDermott DF, Master VA, Signoretti S, et al. . LBA67 phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a national clinical trials network trial. Ann Oncol (2022) 33:S1432–S3. doi: 10.1016/j.annonc.2022.08.072 DOI

Ghali F, Patel SH, Derweesh IH. Current status of immunotherapy for localized and locally advanced renal cell carcinoma. J Oncol (2019) 2019:7309205. doi: 10.1155/2019/7309205 PubMed DOI PMC

Martini A, Fallara G, Pellegrino F, Cirulli GO, Larcher A, Necchi A, et al. . Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma. World J Urol (2021) 39(5):1369–76. doi: 10.1007/s00345-020-03550-z PubMed DOI

Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. . Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol (2018) 29(8):1853–60. doi: 10.1093/annonc/mdy218 PubMed DOI PMC

Roussel E, Tasso G, Campi R, Kriegmair MC, Kara Ö, Klatte T, et al. . Surgical management and outcomes of renal tumors arising from horseshoe kidneys: results from an international multicenter collaboration. Eur Urol (2021) 79(1):133–40. doi: 10.1016/j.eururo.2020.09.012 PubMed DOI

Chapin BF, Delacroix SE, Jr., Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, et al. . Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol (2011) 60(5):964–71. doi: 10.1016/j.eururo.2011.05.032 PubMed DOI PMC

Pignot G, Thiery-Vuillemin A, Walz J, Lang H, Bigot P, Werle P, et al. . Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge? Eur Urol (2020) 77(6):761–3. doi: 10.1016/j.eururo.2019.12.018 PubMed DOI

Studentova H, Zemankova A, Spisarova M, Skanderova D, Tudos Z, Melichar B, et al. . A pathological complete response to the combination of ipilimumab and nivolumab in a patient with metastatic renal cell carcinoma. Medicina (Kaunas) (2022) 58(3). doi: 10.3390/medicina58030336 PubMed DOI PMC